The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia

Am J Hematol. 2020 Feb;95(2):E34-E35. doi: 10.1002/ajh.25676. Epub 2019 Dec 2.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Dexamethasone / administration & dosage
  • Humans
  • Leukemia, Plasma Cell* / drug therapy
  • Leukemia, Plasma Cell* / metabolism
  • Leukemia, Plasma Cell* / pathology
  • Male
  • Sulfonamides / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • daratumumab
  • Dexamethasone
  • venetoclax